RxDoctor Payments Data

Michael Grad, MD

Cardiovascular Disease · Austin, TXNPI 1386629012

Payments from drug & device makers

$37,819in general payments, 2019–2025

Across 1,491 payments — averaging $25.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$7K
  • Amgen$3K
  • Johnson & Johnson$2K
  • Novartis$2K
  • Shockwave Medical, Inc$1K
  • Pfizer$1K
  • plus $21K from 54 others

What the payments were for

  • Travel & lodging$2691%
  • Food & beverage$37,46099%
  • Education$900%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott115$7,165
Amgen137$2,679
Johnson & Johnson145$2,249
Novartis111$1,794
Shockwave Medical, Inc15$1,456
Pfizer84$1,448
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)84$1,436
Biosense Webster, Inc.26$1,383
Amarin Pharma, Inc.102$1,344
Sanofi-aventis U.S. LLC37$1,334
Abiomed24$1,312
E.r. Squibb & Sons, L.L.C.94$1,174
Boston Scientific20$1,149
Impulse Dynamics (USA) Inc.35$1,118
Novo Nordisk51$1,058
AstraZeneca56$1,048
Atricure, Inc.10$879
Boehringer Ingelheim41$763
Esperion Therapeutics, Inc.46$753
Bayer19$674
Regeneron Healthcare Solutions, Inc.23$575
Merck27$478
Medtronic(2 entities)15$445
Penumbra, Inc.4$432
Kiniksa Pharmaceuticals, Ltd.14$297
Irhythm Technologies, Inc.7$278
Arbor Pharmaceuticals, Inc.15$226
Alnylam Pharmaceuticals Inc.7$219
Chiesi USA, Inc.12$212
Kowa Pharmaceuticals America, Inc.14$178
Cardiva Medical, Inc.3$178
Bolton Medical Inc6$156
Inspire Medical Systems, Inc.5$155
Heartflow, Inc.1$146
Actelion Pharmaceuticals US, Inc.17$143
Lexicon Pharmaceuticals, Inc.5$128
Kiniksa Pharmaceuticals International, PLC4$116
Lundbeck LLC6$111
Angiodynamics, Inc.2$97
Bardy Diagnostics, Inc.4$90
GSK4$89
Teleflex LLC6$87
Scpharmaceuticals Inc.5$77
Azurity Pharmaceuticals, Inc.4$77
Tactile Systems Technology Inc5$75
Baxter Healthcare3$70
Vital Connect, Inc3$61
Itamar Medical Inc1$61
Cvrx, Inc.2$48
GE HealthCare2$46
Corcept Therapeutics2$33
Myocardial Solutions, Inc.1$33
G Medical Diagnostic Services, Inc.2$32
Edwards Lifesciences2$31
Agepha Pharma FZ LLC1$29
Medicure Pharma Inc.1$26
Lantheus Medical Imaging, Inc.1$22
AbbVie1$19
DJO, LLC1$18
Althera Pharmaceuticals LLC1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,819 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$317,114
Medicare patients
1,194
Services billed
4,822

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban394$478,050
XareltoRivaroxaban138$177,582
Repatha SureclickEvolocumab160$162,447
EntrestoSacubitril/Valsartan50$54,663
BrilintaTicagrelor27$29,117
JardianceEmpagliflozin18$28,325
VascepaIcosapent Ethyl50$27,488
Repatha PushtronexEvolocumab28$25,316
EdarbyclorAzilsartan Med/Chlorthalidone37$20,939
Praluent PenAlirocumab27$19,382
EdarbiAzilsartan Medoxomil27$14,918
Atorvastatin Calcium1,078$10,213
Metoprolol Succinate599$9,741
Ezetimibe382$8,727
Rosuvastatin Calcium489$7,597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,448$478,050394 claims
Johnson & JohnsonXarelto$2,249$177,582138 claims
NovartisEntresto$1,794$54,66350 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$226$35,85664 claims
AstraZenecaBrilinta$1,048$29,11727 claims
Boehringer IngelheimJardiance$763$28,32518 claims
Kowa Pharmaceuticals America, Inc.Livalo$178$6,43318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →